Securities Class Action Filed Against Taro Pharmaceutical Industries
Last Updated on May 8, 2018
Speakes et al v. Taro Pharmaceutical Industries, Ltd. et al
Filed: October 25, 2016 ◆§ 1:16-cv-08318
Taro Pharmaceutical Industries Ltd. and its CEO and CFO are facing a new class action lawsuit filed by a New York plaintiff.
Taro Pharmaceutical Industries Ltd. and its CEO and CFO are facing a new class action lawsuit filed by a New York plaintiff who claims he purchased the company’s stock at artificially inflated prices. According to the complaint, the company has issued materially false and misleading statements that misrepresented certain aspects of its financial outlook and competitive landscape. Specifically, plaintiffs allege that “since 2014 Taro has colluded with other pharmaceutical companies to keep the price of generic products artificially high,” as well as engaged in conduct that violated federal antitrust laws. As a result, Taro’s revenue during the class period— July 3, 2014 through September 9, 2016—was produced through illegal activity.
On September 8, 2016, the defendants received grand jury subpoenas from the U.S. Department of Justice’s Antitrust Division looking for records related to Taro’s products, employee records and communications with competitors. When this was made public, Taro stock prices fell almost four percent. More than a month after the DOJ subpoenas were issued, a class action was filed against Taro and other pharmaceutical companies claiming they fixed the prices of Clobetasol, a popular generic drug used to treat skin conditions, since 2014.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.